← 返回

弥漫大 B 细胞淋巴瘤中坏死性凋亡相关基因在临床预后和免疫细胞中的识别与评估

英文原题:Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.

查看英文原题

Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.

PubMed 2022/06/22(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们从多个角度探索了坏死性凋亡在 DLBCL 中的潜在作用,并为 DLBCL 的生存预测提供了预后列线图。坏死性凋亡在 DLBCL 中下调,并与免疫抑制的肿瘤微环境和不良预后相关。我们的研究可能加深对 DLBCL 的理解,并促进新治疗靶点的开发。

研究思路结论见上方概要

随着新机制的揭示和新药的出现,弥漫性大B细胞淋巴瘤(DLBCL)的预后变得乐观,但仍有部分患者进展至复发或难治阶段。坏死性凋亡作为一种相对较新的程序性细胞死亡方式,参与多种肿瘤的发生发展。迄今为止,尚无关于坏死性凋亡在DLBCL中预后意义的相关研究。

我们通过比较GSE12195和GSE56315数据集中的DLBCL和正常对照,鉴定了差异坏死性凋亡相关基因(NRGs)。将包含临床信息和微阵列表达谱的TCGA DLBC和GSE10846合并为整个队列。我们基于NRGs进行了共识聚类,获得了两个聚类。采用Kaplan-Meier(K-M)生存分析、GSVA、GO、KEGG和ssGSEA分析两个聚类之间的生存、功能和免疫微环境。通过LASSO和比例风险模型构建,我们鉴定了NRG聚类之间的差异表达基因(DEGs),计算了风险评分,建立了预后模型,并通过校准曲线和ROC曲线验证了其价值。整个队列被分为训练队列和测试队列,GSE87371作为外部验证队列纳入。还分析了K-M、拷贝数变异、肿瘤突变负荷和药物敏感性。

我们发现两个NRG亚群之间的预后存在显著差异。预后较差的A亚群表现出NRGs表达降低及免疫微环境相对受抑。GSVA分析表明,A亚群与TGF-β信号通路下调及Notch信号通路激活相关。风险评分具有准确的预测能力。列线图有助于预测整个队列及外部验证队列中DLBCL患者的生存概率。列线图、风险评分及国际预后指数的曲线下面积(AUC)分别为0.723、0.712和0.537。在高风险组中,γ/δ T细胞和巨噬细胞1型细胞减少,而巨噬细胞2型细胞和自然杀伤静息细胞增加。此外,高风险组对PI3K抑制剂和PDK抑制剂更为敏感。

展开英文摘要原文

With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. Necroptosis, as a relatively novel programmed cell death, is involved in the development of multiple tumors. There are no relevant studies on the prognostic significance of necroptosis in DLBCL to date.

We identified the differential necroptosis-related genes (NRGs) by comparing the DLBCL and normal control in GSE12195 and GSE56315 datasets. TCGA DLBC and GSE10846 containing clinical information and microarray expression profiling were merged as the entire cohort. We performed consensus clusters based on NRGs and two clusters were obtained. Kaplan-Meier (K-M) survival analysis, GSVA, GO, KEGG, and ssGSEA were used to analyze the survival, function, and immune microenvironment between two clusters. With LASSO and proportional hazard model construction, we identified differentially expressed genes (DEGs) between NRG clusters, calculated the risk score, established a prognostic model, and validated its value by calibration and ROC curves. The entire cohort was divided into the training and test cohort, and GSE87371 was included as an external validation cohort. K-M, copy number variation, tumor mutation burden, and drug sensitivity were also analyzed.

We found significant differences in prognosis between the two NRG clusters. Cluster A with a poor prognosis had a decreased expression of NRGs and a relatively suppressed immune microenvironment. GSVA analysis indicated that cluster A was related to the downregulation of the TGF-β signaling pathway and the activation of the Notch signaling pathway. The risk score had an accurate predictive ability. The nomogram could help predict the survival probability of DLBCL patients in the entire cohort and the external validation cohort. The area under the curve (AUC) of the nomogram, risk score, and International Prognostic Index was 0.723, 0.712, and 0.537, respectively. γ/δ T cells and Macrophage 1 cells decreased while Macrophage 2 cells and Natural Killer resting cells increased in the high-risk group. In addition, the high-risk group was more sensitive to the PI3K inhibitor and the PDK inhibitor.

We explored the potential role of necroptosis in DLBCL from multiple perspectives and provided a prognostic nomogram for the survival prediction of DLBCL. Necroptosis was downregulated and was correlated with an immunosuppressed tumor microenvironment and poor prognosis in DLBCL. Our study may deepen the understanding and facilitate the development of new therapy targets for DLBCL.

论文信息

作者
Zhang Q、Zhu Z、Guan J、Zheng C
单位
Department of Hematological Oncology, Wenzhou Central Hospital, The Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, China.China
期刊
Frontiers in oncology2022
原文标识
PubMed 35814424 · DOI 10.3389/fonc.2022.904614